Intrinsic Therapeutics Completes $52m Financing to Fuel Commercial Efforts in the United States to Benefit Lumbar Discectomy Patients
BOSTON, April 11, 2019 /PRNewswire/ — Intrinsic Therapeutics, Inc., a medical device company focusing on surgeries to treat leg and low back pain…Read More »
Intrinsic Therapeutics announces the Filing of PMA Application for its Barricaid® Anular Closure Device for Lumbar Discectomy Patients.
BOSTON, Dec. 21, 2016 /PRNewswire/ — Intrinsic Therapeutics, Inc. announced today that the filing of its Pre-Market Approval (PMA) application with the Food…Read More »
WOBURN, Mass., Feb. 17, 2011 /PRNewswire/ — Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that…Read More »